NEUREGULINS AND NIGROSTRIATAL SYSTEM FUNCTION

神经调节蛋白和黑质纹状体系统功能

基本信息

  • 批准号:
    6639597
  • 负责人:
  • 金额:
    $ 26.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-04-10 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (From the applicant's abstract): Parkinson's disease is characterized by the progressive degeneration of nigrostriatal dopaminergic neurons in the ventral midbrain. Although the basic underlying mechanisms of this debilitating movement disorder remain unknown, considerable efforts have centered on developing effective strategies for halting the neurodegenerative process and restoring normal function. One promising approach involves the use of neurotrophic factors, proteins that promote the survival and proper functioning of select populations of neurons. Preliminary findings from our laboratory show that receptor mRNA and protein for a relatively novel group of trophic factors called neuregulins are synthesized within the dopaminergic nigrostriatal system in rodents and primates. We find that supranigral administration of neuregulin induces increased dopamine overflow in the striatum, indicating functional effects upon the dopaminergic nigrostriatal system. Our recent data also indicate that neuregulin treatment protects dopaminergic cells against neurotoxin-induced degeneration in vivo, and against both oxidative and metabolic insults in vitro. In the proposed research, we will expand upon these findings to test the overall the hypothesis that neuregulins are neuroprotective and/ or neurorestorative for midbrain dopaminergic neurons upon selective neurotoxic damage. Specific Aim #1 will determine the extent to which neuregulin receptors are expressed by dopaminergic cells in the ventral mesencephalon of normal and neurotoxin-lesioned rat and monkey using single- and double-labeling in situ hybridization and immunocytochemical techniques. Specific Aim #2 will use a well-characterized rat model of Parkinson's disease coupled with specific neuregulin treatment regims to test if infusion of neuregulins (I) protects dopaminergic neurons from subsequent neurotoxic damage or (ii) promotes functional recovery of the injured nigrostriatal system after neurotoxic damage. Morphological, behavioral and neurochemical approaches will be used to analyze the extent of protection and/or functional restoration afforded by neuregulin treatment. Specific aim #3 will (I) determine if neuregulin receptor expression is spatially or temporally deficient in the rat and monkey nigrostriatal system in aged animals, and (ii) using intracerebral microdialysis, evaluate the responsiveness of the dopaminergic nigrostriatal system to neuregulin administration in young, middle age and old rats. Specific aim #4 will assess the potential mechanisms by which neuregulin protects dopaminergic cells from insults relevent to Parkinson's disease. Overall, these studies will assess the therapeutic value of neuregulin trophic factors for the treatment of Parkinson's disease and other neurodegenerative disorders of the nigrostriatal system.
描述(来自申请人的摘要):帕金森病是 以黑质纹状体多巴胺能神经元的进行性变性为特征, 中脑腹侧的神经元虽然基本的潜在机制, 这种使人衰弱的运动障碍仍然是未知的,相当大的努力, 致力于开发有效的策略, 并恢复正常功能。一种有希望的方法是使用 神经营养因子,蛋白质,促进生存和适当的 选择神经元群体的功能。我们的初步调查结果 实验室显示,一组相对较新 称为神经调节素的营养因子在多巴胺能神经元内合成。 啮齿类和灵长类的黑质纹状体系统。我们发现, 神经调节素的施用诱导增加的多巴胺溢出, 纹状体,表明对多巴胺能黑质纹状体的功能影响 系统我们最近的数据还表明,神经调节蛋白治疗可以保护 多巴胺能细胞对抗体内神经毒素诱导的变性, 体外氧化和代谢损伤。在这项研究中,我们 我将在这些发现的基础上进行扩展,以检验总体假设, 神经调节蛋白对中脑具有神经保护和/或神经恢复作用 多巴胺能神经元的选择性神经毒性损伤。具体目标#1 确定神经调节蛋白受体表达的程度, 多巴胺能细胞在腹侧中脑正常和 神经毒素损伤大鼠和猴的原位单标记和双标记 杂交和免疫细胞化学技术。具体目标#2将使用 帕金森病的良好表征的大鼠模型加上特定的 neuregulin治疗方案,以测试输注neuregulin(I)是否保护 多巴胺能神经元免受随后的神经毒性损伤,或(ii)促进 神经毒性后受损黑质纹状体系统的功能恢复 损害形态学、行为学和神经化学方法将用于 分析保护和/或功能恢复的程度, neuregulin治疗具体目标#3将(I)确定神经调节蛋白受体 表达在大鼠和猴中是空间或时间缺陷的 老年动物的黑质纹状体系统,和(ii)使用脑内 微透析,评估多巴胺能黑质纹状体的反应性 系统对年轻、中年和老年大鼠施用神经调节蛋白的影响。具体 目的#4将评估neuregulin保护的潜在机制 多巴胺能细胞免受帕金森氏病相关损伤。总的来说,这些 研究将评估神经调节蛋白营养因子对 帕金森氏病和其他神经变性疾病的治疗 黑质纹状体系统

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Supranigral injection of neuregulin1-beta induces striatal dopamine overflow.
黑猩猩上注射神经调节蛋白1-β可诱导纹状体多巴胺溢出。
  • DOI:
    10.1016/j.brainres.2004.08.066
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yurek,DavidM;Zhang,Lixin;Fletcher-Turner,Anita;Seroogy,KimB
  • 通讯作者:
    Seroogy,KimB
Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats.
  • DOI:
    10.1016/j.neuroscience.2009.06.008
  • 发表时间:
    2009-09-29
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Dickerson, J. W.;Hemmerle, A. M.;Numan, S.;Lundgren, K. H.;Seroogy, K. B.
  • 通讯作者:
    Seroogy, K. B.
(±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.
  • DOI:
    10.1002/cne.23048
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Hemmerle, Ann M.;Dickerson, Jonathan W.;Herring, Nicole R.;Schaefer, Tori L.;Vorhees, Charles V.;Williams, Michael T.;Seroogy, Kim B.
  • 通讯作者:
    Seroogy, Kim B.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KIM B SEROOGY其他文献

KIM B SEROOGY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KIM B SEROOGY', 18)}}的其他基金

Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    8269921
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    7625140
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    7848394
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    7526354
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    8078816
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
Stress-Induced Depression and Parkinsonian Symptomology
压力诱发的抑郁症和帕金森病症状
  • 批准号:
    7848068
  • 财政年份:
    2008
  • 资助金额:
    $ 26.86万
  • 项目类别:
NEUROPEPTIDES 2003 Symposium: Alzheimer's Disease
2003 年神经肽研讨会:阿尔茨海默病
  • 批准号:
    6679501
  • 财政年份:
    2003
  • 资助金额:
    $ 26.86万
  • 项目类别:
NEUROPEPTIDES 2003: STUDENT TRAVEL
神经肽 2003:学生旅行
  • 批准号:
    6673479
  • 财政年份:
    2003
  • 资助金额:
    $ 26.86万
  • 项目类别:
2002 Summer Neuropeptide Conference: Student Travel
2002年夏季神经肽会议:学生旅行
  • 批准号:
    6508560
  • 财政年份:
    2002
  • 资助金额:
    $ 26.86万
  • 项目类别:
Neuropeptides 2001: Alzheimer's Disease Symposium
神经肽 2001:阿尔茨海默病研讨会
  • 批准号:
    6369330
  • 财政年份:
    2001
  • 资助金额:
    $ 26.86万
  • 项目类别:

相似海外基金

Development and Translation Mass Spectrometry Methods to Determine BioMarkers for Parkinson's Disease and Comorbidities
确定帕金森病和合并症生物标志物的质谱方法的开发和转化
  • 批准号:
    2907463
  • 财政年份:
    2024
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Studentship
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
  • 批准号:
    MR/Y019415/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Research Grant
Promoting Parkinson's disease trial participation in rural and coastal communities
促进农村和沿海社区参与帕金森病试验
  • 批准号:
    2898794
  • 财政年份:
    2024
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Studentship
Neurophysiological mechanism underlying freezing of gait in Parkinson's disease: transcutaneous spinal cord stimulation for gait disturbance
帕金森病步态冻结的神经生理机制:经皮脊髓刺激治疗步态障碍
  • 批准号:
    23K10409
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Inhibition of cell-to-cell propagation of alpha-synuclein aggregation by glial cells and its involvement in neuropathology in Parkinson's disease.
神经胶质细胞抑制α-突触核蛋白聚集的细胞间传播及其参与帕金森病的神经病理学。
  • 批准号:
    23K06928
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Propagation of a-synuclein in Parkinson's disease progress
α-突触核蛋白在帕金森病进展中的传播
  • 批准号:
    22KJ2095
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The Diagnostic and Prognostic Utility of Eye Tracking in Parkinson's Disease and Related Disorders
眼动追踪在帕金森病及相关疾病中的诊断和预后效用
  • 批准号:
    479285
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Operating Grants
Drug-microbiome-host interactions in Parkinson's disease
帕金森病的药物-微生物组-宿主相互作用
  • 批准号:
    2881438
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Studentship
MICA: How does the pedunculopone nucleus influence treatment responses in Parkinson's disease, and can it be targeted for new treatment strategies
MICA:脚核如何影响帕金森病的治疗反应,是否可以作为新治疗策略的目标
  • 批准号:
    MR/X005267/1
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Research Grant
Ordering the disordered in Parkinson's disease to derive peptide inhibitors of alpha-synuclein toxicity
命令帕金森病患者衍生出α-突触核蛋白毒性的肽抑制剂
  • 批准号:
    2884235
  • 财政年份:
    2023
  • 资助金额:
    $ 26.86万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了